FBR & Co reaffirmed their hold rating on shares of Zafgen Inc. (NASDAQ:ZFGN) in a report published on Tuesday morning.

A number of other analysts have also issued reports on ZFGN. Cowen and Company lowered Zafgen from an outperform rating to a market perform rating in a report on Wednesday, July 20th. Leerink Swann restated a market perform rating and issued a $6.00 target price on shares of Zafgen in a report on Wednesday, July 20th. Canaccord Genuity set a $4.00 price objective on Zafgen and gave the stock a hold rating in a report on Thursday, July 21st. Finally, Zacks Investment Research upgraded Zafgen from a hold rating to a buy rating and set a $3.50 price objective for the company in a report on Tuesday, July 26th. Six analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of Hold and a consensus target price of $14.22.

Zafgen (NASDAQ:ZFGN) traded down 2.545% on Tuesday, hitting $3.255. The company had a trading volume of 1,411,072 shares. The stock’s market cap is $88.96 million. Zafgen has a 12-month low of $2.90 and a 12-month high of $44.98. The firm’s 50 day moving average price is $3.13 and its 200 day moving average price is $5.42.

In other Zafgen news, CFO Patricia L. Allen bought 16,000 shares of the stock in a transaction on Tuesday, July 26th. The shares were purchased at an average cost of $3.12 per share, with a total value of $49,920.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frances K. Heller bought 10,000 shares of the stock in a transaction on Friday, July 22nd. The shares were acquired at an average cost of $2.99 per share, for a total transaction of $29,900.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $29,900. The disclosure for this purchase can be found here. Company insiders own 20.30% of the company’s stock.

A number of institutional investors have recently bought and sold shares of ZFGN. Alliancebernstein L.P. acquired a new position in Zafgen during the second quarter valued at approximately $114,000. Bellevue Group AG acquired a new stake in shares of Zafgen during the first quarter valued at about $134,000. ProShare Advisors LLC increased its stake in shares of Zafgen by 4.9% in the second quarter. ProShare Advisors LLC now owns 23,099 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 1,075 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Zafgen by 103.0% in the second quarter. Rhumbline Advisers now owns 34,692 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 17,602 shares in the last quarter. Finally, Alps Advisors Inc. increased its stake in shares of Zafgen by 25.1% in the second quarter. Alps Advisors Inc. now owns 38,312 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 7,683 shares in the last quarter. 62.83% of the stock is currently owned by hedge funds and other institutional investors.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

5 Day Chart for NASDAQ:ZFGN

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.